Deals - Generic companies looking to increase scale, revenue, market share, and competitive advantage have been active with mergers and acquisitions driven by need for backward integration into active pharmaceutical ingredients, expansion into smaller and emerging markets, and portfolio build-outs in niche, specialty, and biologics products.
Download the Newport Deals white paper PDF
Biologics - Entry of biosimilar therapies in the U.S. market is expected within the next few years due to loss of exclusivity and patent protection of the top-selling products. Understanding what to expect from the follow-on biologics market will be critical for successful competition, both in the U.S. and globally.
Download the Newport Biologics white paper PDF
Japanese Generic - In this important new white paper, Thomson Reuters reveals the true picture of the generic market in Japan, predicts how it may change under the incoming DPJ administration, and details the tactics that companies must follow to ensure success in this market.
Download the Newport Japanese Generic white paper PDF
5 Myths - In this white paper, Thomson Reuters exposes the myths about generic competition, and shows what originators can do to predict its likely timing, source, and intensity.
Download the Newport 5 Myths white paper PDF